Method for the diagnosis of preeclampsia

Abstract

The present invention relates to a biomarker and a composition for diagnosis of preeclampsia. In accordance with one aspect of the present invention, there is provided a biomarker for diagnosis of preeclampsia using an enzyme selected from the group consisting of placental chondroitin 4-O-sulfotransferase 1 (C4ST), chondroitin 6-sulfotransferase (C6S), heparan sulfate 6-O-sulfotransferase 1 (HS6S), and dermatan/chondroitin sulfate 2-sulfotransferase (CS-2OST), or uronic acid-2-sulfate (UA2S).

1 - 4 . (canceled) 
     
     
         5 . A method for identifying preeclampsia of pregnancy in a pregnant woman, the method comprising:
 isolating a placental tissue from the pregnant woman;   performing RT-PCR assays to detect the level of chondroitin 6-sulfotransferase (C6S) in the isolated placental tissue of the pregnant woman;   measuring an amount of mRNA of the C6S by Quantitative Real-Time PCR (qRT-PCR); and   identifying preeclampsia of pregnancy in the pregnant woman based on the amount of mRNA of the C6S from the isolated placental tissue of the pregnant woman, wherein an amount of mRNA of the C6S in a placental tissue of a pregnant woman having preeclampsia is lower than an amount of mRNA of the C6S in a placental tissue of a pregnant woman who does not have preeclampsia.   
     
     
         6 . The method of  claim 5 , further comprising:
 comparing the amount of mRNA of the C6S in the isolated placental tissue of the pregnant woman with the amount of mRNA of the C6S in the placental tissue of the pregnant woman who does not have preeclampsia.